Cytocompatibility evaluation of a novel series of PEG-functionalized lactide-caprolactone copolymer biomaterials for cardiovascular applications

  • Although the use of bioresorbable materials in stent production is thought to improve long-term safety compared to their durable counterparts, a recent FDA report on the 2-year follow-up of the first FDA-approved bioresorbable vascular stent showed an increased occurrence of major adverse cardiac events and thrombosis in comparison to the metallic control. In order to overcome the issues of first generation bioresorbable polymers, a series of polyethylene glycol-functionalized poly-L-lactide-co-\(\epsilon\)-caprolactone copolymers with varying lactide-to-caprolactone content is developed using a novel one-step PEG-functionalization and copolymerization strategy. This approach represents a new facile way toward surface enhancement for cellular interaction, which is shown by screening these materials regarding their cyto- and hemocompatibility in terms of cytotoxicity, hemolysis, platelet adhesion, leucocyte activation and endothelial cell adhesion. By varying the lactide-to-caprolactone polymer composition, it is possible to gradually affect endothelial and platelet adhesion which allows fine-tuning of the biological response based on polymer chemistry. All polymers developed were non-cytotoxic, had acceptable leucocyte activation levels and presented non-hemolytic (<2% hemolysis rate) behavior except for PLCL-PEG 55:45 which presented hemolysis rate of 2.5% \(\pm\) 0.5. Water contact angles were reduced in the polymers containing PEG functionalization (PLLA-PEG: 69.8° \(\pm\) 2.3, PCL-PEG: 61.2° \(\pm\) 7.5) versus those without (PLLA: 79.5° \(\pm\) 3.2, PCL: 76.4° \(\pm\) 10.2) while the materials PCL-PEG550, PLCL-PEG550 90:10 and PLCL-PEG550 70:30 demonstrated best endothelial cell adhesion. PLLA-PEG550 and PLCL-PEG550 70:30 presented as best candidates for cardiovascular implant use from a cytocompatibility perspective across the spectrum of testing completed. Altogether, these polymers are excellent innovative materials suited for an application in stent manufacture due to the ease in translation of this one-step synthesis strategy to device production and their excellent \(\textit {in vitro}\) cyto- and hemocompatibility.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Sandra PacharraGND, Seán McMahonGND, Patrick DuffyGND, Pooja BasnettGND, Wenfa YuGND, Sabine SeiselORCiDGND, Ulrik Stervbo-KristensenORCiDGND, Nina BabelORCiDGND, Ipsita RoyGND, Richard ViebahnORCiDGND, Wenxin WangGND, Jochen SalberGND
URN:urn:nbn:de:hbz:294-75976
DOI:https://doi.org/10.3389/fbioe.2020.00991
Parent Title (English):Frontiers in bioengineering and biotechnology
Publisher:Frontiers Media
Place of publication:Lausanne
Document Type:Article
Language:English
Date of Publication (online):2020/10/29
Date of first Publication:2020/08/13
Publishing Institution:Ruhr-Universität Bochum, Universitätsbibliothek
Tag:Open Access Fonds
bioresorbable; cytocompatibility; poly-L-lactide; poly-\(\epsilon\)-caprolactone; polyethylene glycol
Volume:8
Issue:Article 991
First Page:991-1
Last Page:991-15
Note:
Article Processing Charge funded by the Deutsche Forschungsgemeinschaft (DFG) and the Open Access Publication Fund of Ruhr-Universität Bochum.
Institutes/Facilities:Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Chirurgische Klinik und Poliklinik
Knappschaftskrankenhaus Bochum, Chirurgische Klinik
Dewey Decimal Classification:Technik, Medizin, angewandte Wissenschaften / Medizin, Gesundheit
open_access (DINI-Set):open_access
Licence (English):License LogoCreative Commons - CC BY 4.0 - Attribution 4.0 International